Pittsburgh Paints Co. Introduces PITTSBURGH PAINTS Protective Coatings The Pittsburgh Paints Company launched the PITTSBURGH PAINTS™ Protective Coatings brand, the new face of PPG HIGH PERFORMANCE COATINGS™. In addition to the new brand’s offerings of industry-leading, full-system solutions, trusted products…
Nephrodite’s Holly™ Implantable Continuous Dialysis System Awarded Selection into FDA’s TAP to Accelerate Development and Patient Access Nephrodite, Inc., a medical device company developing an implantable, continuous renal replacement system, announced that its Holly™ system has been selected to participate in…
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy…
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC) Gilead Sciences, Inc. announced positive results from a Phase 3 study in people with primary biliary cholangitis (PBC), showing that treatment with…
Wiley Acquires Emerald, Expanding Research Scale and Deepening Proprietary Content Across the AI-Driven Knowledge Economy Wiley a global leader in authoritative content and research intelligence, announced it has acquired Emerald Publishing Limited (“Emerald”) from Cambridge Information Group (CIG) in an…
GE HealthCare Focuses on Expanding Access to Nuclear Medicine Through AI, Radiopharmaceutical and Imaging Innovations As theranostics adoption acceleratesi and radiopharmaceutical demand grows,ii healthcare systems are under increasing pressure to scale nuclear medicine operations while improving diagnostic confidence and workflow efficiency. At…
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement Rallybio Corporation and Avenzo Therapeutics, Inc. a clinical-stage biotechnology company developing next-generation oncology therapies, announced that they have entered into a definitive…
Single Blood Test Simultaneously Captures Immune, Stromal, and Tumor Signals Linked to Immunotherapy Response and Resistance in Sarcoma Aqtual, Inc., a precision medicine company developing active chromatin cell-free DNA (cfDNA) diagnostics for oncology and chronic disease, announced new findings demonstrating…
Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer Qurient Co., Ltd. announced that the first patient has been dosed in a Phase 2 clinical study evaluating…
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors PanTher Therapeutics a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, announced…
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Merck known as MSD outside of the United States and Canada, announced that…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…